Protocol Ledger

NCT06552520 · Phase III · ACTIVE NOT RECRUITING

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Interventional Phase III clinical trial protocol NCT06552520 sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-08 Enrollment: 500 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06552520
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06552520
Protocol FieldVerified Registry Value
NCT IdentifierNCT06552520
Consolidated Lead SponsorShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment500 participants (ACTUAL)
Registered Start Date2024-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI